[A25-18] Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V
Last updated 07.05.2025
Project no.:
A25-18
Commission:
Commission awarded on 04.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
| Project no. | Title | Status |
|---|---|---|
| A17-39 | Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-19 | Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission work started |